Turtle Creek Wealth Advisors LLC Buys 261 Shares of Stryker Co. (NYSE:SYK)

Turtle Creek Wealth Advisors LLC lifted its stake in Stryker Co. (NYSE:SYK) by 1.6% in the 4th quarter, HoldingsChannel reports. The fund owned 16,560 shares of the medical technology company’s stock after purchasing an additional 261 shares during the quarter. Stryker comprises 1.4% of Turtle Creek Wealth Advisors LLC’s investment portfolio, making the stock its 21st largest position. Turtle Creek Wealth Advisors LLC’s holdings in Stryker were worth $5,962,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Dunhill Financial LLC grew its stake in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Stryker in the third quarter worth about $36,000. Crews Bank & Trust purchased a new stake in shares of Stryker during the fourth quarter worth about $39,000. Hara Capital LLC acquired a new position in shares of Stryker during the third quarter valued at about $42,000. Finally, HBW Advisory Services LLC purchased a new position in shares of Stryker in the 3rd quarter valued at approximately $42,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.2 %

Shares of SYK stock opened at $390.48 on Friday. The company has a market cap of $148.86 billion, a price-to-earnings ratio of 50.32, a PEG ratio of 2.68 and a beta of 0.95. The stock has a 50 day simple moving average of $376.56 and a 200-day simple moving average of $362.38. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same quarter in the prior year, the business earned $3.46 EPS. On average, equities research analysts expect that Stryker Co. will post 13.53 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is presently 43.30%.

Analyst Ratings Changes

Several analysts have weighed in on SYK shares. Citigroup boosted their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Robert W. Baird upped their target price on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. UBS Group increased their price objective on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lifted their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $416.40.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.